Ad
related to: Australian Pharmaceutical IndustriesClinical-grade Active Pharmaceutical Ingredient apo for clinical research. Clinical-grade Active Pharmaceutical Ingredient API for clinical research.
- Our Team
We are a Canadian biotechnology
company dedicated to the ...
- Products
Find Out What You Need to Know
About Our Products.
- Clinical-Grade API
For Clinical Research. PharmAla
Business.
- PharmAla Business
Clinical-grade API for clinical
research.
- Our Focus
Learn More About PharmAla
Biotech
- PharmAla Biotech
Leading biotech company in
Canada.
- Our Team
Search results
www.api.net.au. Australian Pharmaceutical Industriea (API) is a health and beauty company owned by Wesfarmers. It is involved in pharmaceutical distribution, retailing and manufacturing. API is Australia's largest wholesale distributor of pharmaceutical and allied products. [1]
Australia’s multi-billion-dollar pharmaceutical market has been growing steadily over the past decade and appears to have maintained this growth despite challenges brought on by the...
253. Australian Pharmaceutical Industries (API) | 17,009 followers on LinkedIn. Australian Pharmaceutical Industries Limited (API) is one of Australia’s leading pharmaceutical...
Australian Pharmaceutical Industries. Since its beginnings in 1910, API has grown from a small co-operative of three pharmacies to now one of Australia’s leading health, beauty and wellbeing companies.
Mar 31, 2022 · Wesfarmers acquired Australian Pharmaceutical Industries Limited (API) on 31 March 2022 by way of a scheme of arrangement. As a result, API shares were suspended from close of trading on the ASX on 22 March 2022 and it was delisted from the ASX on 1 April 2022.
Jan 7, 2022 · Jan 7 (Reuters) - Australian Pharmaceutical Industries (API.AX) said on Friday conglomerate Wesfarmers Ltd would buy it for A$763.6 million ($546.9 million) after Woolworths pulled out of a...
Transaction details. Wesfarmers today announced that it has submitted a non-binding, indicative offer to acquire 100 per cent of the shares outstanding in API for $1.38 cash per share by way of a scheme of arrangement. 1.
Ad
related to: Australian Pharmaceutical IndustriesClinical-grade Active Pharmaceutical Ingredient apo for clinical research. Clinical-grade Active Pharmaceutical Ingredient API for clinical research.